FIB-4 Score Positively Linked to Gallstone Risk in US Adults, confirms study

Researchers have discovered in a new study that a greater fibrosis-4 index (FIB-4) score, a noninvasive marker traditionally used to assess liver fibrosis, is strongly associated with an increased risk of gallstones among adults. Gallstones are among the most prevalent gastrointestinal diseases, but their association with markers of fibrosis in the liver such as FIB-4 is poorly understood. The new analysis offers valuable information regarding how biomarkers of the liver may be associated with risk for gallbladder disease in the general population. The study was published in BMC Gastroenterology by Huqiang Dong and colleagues.

The research used 2017–2020 National Health and Nutrition Examination Survey (NHANES) data and involved 7,771 participants. It is one of the largest nationally representative analyses to examine this association in US adults. The investigators examined the association of FIB-4 levels with the presence of gallstones based on data from NHANES, a well-established US population-based survey. The FIB-4 index was derived from age, AST, ALT, and platelet count.

Participants were categorized into quartiles according to their FIB-4 levels, and multivariate logistic regression models were used to examine the association with risk of gallstones. Restricted cubic spline (RCS) analysis was employed to check for nonlinear trends, and threshold effects analysis was utilized to identify inflection points at which risk levels altered. Subgroup analyses were conducted to test consistency within various demographic and health subgroups, and Bonferroni correction was implemented to preserve statistical precision.

Results

The weighted prevalence of gallstones in the study population was 11%. There was a clear and statistically significant positive association between FIB-4 levels and risk of gallstones:

  • For every unit increase in FIB-4, there was a 19% increase in the odds of gallstones (Odds Ratio [OR] = 1.19; 95% Confidence Interval [CI]: 1.10 to 1.29).

  • When quartiled, individuals in the uppermost FIB-4 quartile (Q4) had a 60% increased risk of gallstones (OR = 1.60; 95% CI: 1.25 to 2.03) than those in the lowest quartile (Q1).

  • The RCS analysis found a nonlinear positive relationship between FIB-4 and risk for gallstones with a statistically significant nonlinear trend (p = 0.015). Risk increased sharply beyond an inflection point at a FIB-4 score of 2.43 (p = 0.001).

  • Subgroup analysis validated that the positive correlation between FIB-4 and gallstones persisted strongly among non-Hispanic whites, subjects without heart failure or coronary artery disease, and among alcohol users and smokers. Following Bonferroni adjustment, these correlations persisted statistically significantly (p < 0.00217).

This research firmly determines a strong, nonlinear relationship between FIB-4 elevation and increased gallstone risk in US adults. These findings point to the potential of FIB-4 as an inexpensive, noninvasive gallstone risk marker that is rapid. As gallstones are typically asymptomatic until complications are formed, the value of FIB-4 as an adjunct tool to screening could improve earlier diagnosis and prevention efforts, particularly in high-risk patients.

Reference:

Dong, H., Zhang, Z., Fu, C. et al. Association between fibrosis-4 index (FIB-4) and gallstones: an analysis of the NHANES 2017–2020 cross-sectional study. BMC Gastroenterol 25, 229 (2025). https://doi.org/10.1186/s12876-025-03809-y

Powered by WPeMatico

Low-Dose Sirolimus as Effective as High-Dose for Kaposiform Hemangioendothelioma Treatment, suggests study

Researchers have found in new research that low-dose sirolimus is noninferior to high-dose sirolimus in the treatment of Kaposiform Hemangioendothelioma (KHE), suggesting that lower doses may be a viable treatment option.

It remains unknown whether low-dose sirolimus can replace high-dose sirolimus for the treatment of kaposiform hemangioendothelioma (KHE) without the Kasabach–Merritt phenomenon (KMP). A study was done to evaluate the noninferiority and safety of low-dose versus high-dose sirolimus in Kaposiform Hemangioendothelioma patients. This randomized, multicenter, open-label, noninferiority trial was conducted from February 2021 to August 2022. Participants received either a low-dose sirolimus regimen (blood trough concentration 5-8 ng/mL) or a high-dose sirolimus regimen (blood trough concentration 10-15 ng/mL). The primary endpoint was the difference in the proportion of patients between groups who achieved an objective response, defined as a ≥20% reduction in Kaposiform Hemangioendothelioma volume at month 12. Results: In this study, 39 were in the low-dose group, and 40 were in the high-dose group. At 1 year of treatment, 90.0% in the high-dose group and 89.7% in the low-dose group achieved an objective response (difference, 0.3%; 95% confidence interval -13.1 to 13.6). The incidences of total adverse events (AEs) and serious adverse events were similar between the two groups, but respiratory, skin and mucosal adverse events were less common in the low-dose group. Low-dose sirolimus is noninferior to high-dose sirolimus in treating Kaposiform Hemangioendothelioma.

Reference:

Efficacy and Safety of High- vs Low-Dose Sirolimus in Patients with Kaposiform Hemangioendothelioma: A Randomized Clinical Trial Zhou, Jiangyuan et al. Journal of the American Academy of Dermatology, Volume 0, Issue 0

Keywords:

Efficacy, Safety, High, Low, Dose, Sirolimus, Patients, Kaposiform, Hemangioendothelioma, Trial Zhou, Jiangyuan

Powered by WPeMatico

Ampicillin and Gentamicin Combo bests ampicillin for managing PROM at term: Study

Israel: A recent randomized clinical trial has provided compelling evidence that a combination of ampicillin and gentamicin prophylaxis is more effective than ampicillin alone in managing prelabor rupture of membranes (PROM) at term.

Researchers found that using ampicillin and gentamicin for prophylaxis in term premature rupture of membranes, compared to ampicillin alone, leads to lower rates of clinical chorioamnionitis, maternal postpartum complications, and neonatal adverse outcomes. The finding, published in the American Journal of Obstetrics and Gynecology, suggests the need to reassess the current antimicrobial prophylactic regimen for better maternal and neonatal outcomes.

When the water bag breaks before labor begins, a condition known as PROM, increases the risk of infections in both the mother and baby. Doctors often prescribe ampicillin for patients whose group B Streptococcus (GBS) status is unknown, especially if PROM lasts more than 18 hours. The researchers, however, note that some bacteria, like ampicillin-resistant Enterobacteriaceae, can also cause infections in mothers and newborns. Current guidelines for antibiotic use during labor mainly focus on preventing GBS infections but do not fully address the risk posed by these resistant bacteria.

Against the above background, Maya Frank Wolf, Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel, and colleagues aimed to evaluate the risk of infections in mothers and newborns when treated with two different antibiotic regimens: ampicillin plus gentamicin versus ampicillin alone.

For this purpose, the researchers conducted a randomized-controlled trial at a university hospital between November 2022 and March 2024. They included women with term pregnancies (>37 weeks), unknown GBS status, and PROM without active labor, while excluding those with allergies, contraindications for vaginal delivery, or prior antibiotic use. Participants were randomly assigned to receive either ampicillin plus gentamicin (n=102) or ampicillin alone (n=102).

The primary outcome was clinical chorioamnionitis, while secondary outcomes included maternal infections and neonatal complications: microbiologic analysis and statistical methods assessed risk factors and treatment effectiveness, including multivariate regression.

The key findings of the study were as follows:

  • Fewer cases of clinical chorioamnionitis were seen with ampicillin and gentamicin (1.0% vs. 7.8%).
  • Lower incidence of fever during labor (8.0% vs. 18.0%).
  • Reduced overall risk of infections around childbirth (1.0% vs. 9.8%).
  • To prevent one case of clinical chorioamnionitis, 15 patients need treatment with ampicillin and gentamicin.
  • Fewer postpartum complications in mothers (0% vs. 5.9%).
  • Lower neonatal complications (10.8% vs. 21.6%).
  • Fewer sepsis evaluations in newborns (7.8% vs. 17.6%).
  • Shorter NICU stays (3.0 vs. 3.5 days).
  • Lower presence of resistant bacteria in chorioamniotic samples (20% vs. 51%).Bottom of Form

In term PROM, using ampicillin and gentamicin together significantly reduces the risk of clinical chorioamnionitis, maternal postpartum complications, and neonatal adverse outcomes compared to ampicillin alone.

“These findings highlight the need to reassess the current antibiotic regimen for better infection prevention in mothers and newborns,” the authors concluded.

Reference:

Abu Shqara, R., Glikman, D., Goldinfeld, G., Braude, O., Assy, S., Hassan, D., Sgayer, I., Ganem, N., Shasha-Lavsky, H., Yefet, E., Matanis, M., Lowenstein, L., & Frank Wolf, M. (2025). Ampicillin and gentamicin prophylaxis is superior to ampicillin alone in patients with prelabor rupture of membranes at term: The results of a randomized clinical trial. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2025.03.011

Powered by WPeMatico

Swedish Study significantly links bronchial Asthma with Diabetes

A significant association was found between asthma and type 2 diabetes (T2D), even after adjusting for body mass index (BMI). Additionally, individuals with a sibling affected by one condition had an increased likelihood of having the other condition, indicating shared genetic and environmental factors.

Asthma and type 2 diabetes are two important causes of morbidity globally. They examined both the association of type 2 diabetes with asthma in Swedish adults and the familial co-aggregation of the diseases. They conducted a cross-sectional study of all adults aged 25–85 in Sweden between 2009 and 2013. Asthma and type 2 diabetes status were ascertained from the health registers. Models were adjusted for sex, age, education level, income and country of birth and in a subset, for body mass index (BMI). They further conducted a familial coaggregation analysis to determine if shared familial factors could explain any observed findings. Results The study included 5,299,245 participants, 25,292 (0.5%) had both asthma and type 2 diabetes. In the total population, the OR for the association between type 2 diabetes and asthma was 1.47 (95% CI 1.45 to 1.49); in the population of men (1.30 (95% CI 1.27 to 1.32)) and women (1.63 (95% CI 1.60 to 1.66)). The ORs were slightly higher among men (1.51 (95% CI 1.45 to 1.56)) and women (2.04 (95% CI 1.96 to 2.11)) for whom BMI measurements were available but attenuated with adjustment for BMI (1.45 (95% CI 1.40 to 1.51)) and (1.76 (95% CI 1.68 to 1.84)). Diabetes was more likely if a full sibling had asthma than if the sibling did not (1.13 (95% CI 1.10 to 1.15)). They found an association between asthma and type 2 diabetes that was sustained after adjusting for BMI, indicating that BMI alone does not explain this relationship. They also found that the two conditions coaggregate in siblings, indicating that the association is partly due to shared familial genetic and environmental risk factors.

Reference:

Mubanga M, Gong T, Smew AI, et al. Association between asthma and type 2 diabetes in a Swedish adult population: a register-based cross-sectional study. Thorax Published Online First: 23 March 2025. doi: 10.1136/thorax-2024-222819

Keywords:

Mubanga M, Gong T, Smew AI, Thorax, Association, asthma, type, 2 diabetes, Swedish, adult, population, register-based, cross-sectional, study

Powered by WPeMatico

Menopause symptoms associated with future memory and neuropsychiatric problems: Study

Women who exhibit more menopausal symptoms are more likely to later have poorer cognitive function and mild behavioral impairments-both markers of dementia. That is the conclusion of a study of 896 postmenopausal females published March 5, 2025, in the open-access journal PLOS One by Zahinoor Ismail of University of Calgary, Canada, and colleagues.

Females are known to have a three-fold greater risk of developing Alzheimer’s disease and related dementias, and will be disproportionately affected by the increasing global dementia burden. A proposed factor that may confer special risk to females is the loss of estradiol at menopause.

In the new study, researchers used data from the ongoing Canadian Platform for Research Online to Investigate Health, Quality of Life, Cognition, Behaviour, Function, and Caregiving in Aging (CAN-PROTECT) study. Data on 896 respondents who completed demographic, cognitive, and behavioral assessments and reported being post-menopausal were included. Participants had an average age of 64.2 years and an average age at menopause onset of 49.4 years.

Menopausal symptom burden was assessed by summing the total number of recalled perimenopausal symptoms, including irregular periods, hot flashes, chills, vaginal dryness, weight gain, slowed metabolism, night sweats, sleep problems, mood symptoms, inattention or forgetfulness, and other unnamed symptoms. The study found that women who reported more perimenopausal symptoms had greater cognitive impairment, with higher ECog-II total scores (b [95% confidence interval (CI)] = 5.37 [2.85, 7.97]). They also had more mild behavioral impairment symptoms in mid- to late life, with higher MBI-C total scores (b [95% CI] = 6.09 [2.50, 9.80]). Hormone therapy was not significantly associated with cognitive function but was linked to fewer behavioral symptoms.

The authors conclude that a higher menopausal symptom burden may indicate susceptibility to cognitive and behavioral changes later in life. The study acknowledges the need for further investigation to confirm these findings in a larger dataset, ideally with a longitudinal design to allow for determination of causality. Further segregation of the participants to account for confounding risk factors, including age of menopausal onset or surgical menopause intervention, would also benefit future studies.

The authors add: “Greater menopausal symptom burden may be associated with greater cognitive and behavioral decline in later life, both risk markers of dementia. Estrogen-based hormone therapy may contribute to mitigating clinical symptoms, particularly behavioral symptoms.”

Reference:

Jasper F. E. Crockford,Dylan X. Guan,Gillian Einstein,Clive Ballard,Byron Creese,Anne Corbett,Ellie Pickering,Adam Bloomfield,Pamela Roach,Eric E. Smith,Zahinoor Ismail, Menopausal symptom burden as a predictor of mid- to late-life cognitive function and mild behavioral impairment symptoms: A CAN-PROTECT study, PLOS One, https://doi.org/10.1371/journal.pone.0301165.

Powered by WPeMatico

Over-the-counter pain relievers linked to improved recovery from concussion, finds study

 People who take over-the-counter pain relievers after a concussion may recover faster than those who do not take pain relievers, according to a preliminary study released today, March 5, 2025, that will be presented at the American Academy of Neurology’s 77th Annual Meeting taking place April 5–9, 2025, in San Diego and online.

The study does not prove that pain relievers improve recovery after concussion; it only shows an association.

“These results are exciting as there are limited treatment options for concussion, and over-the-counter pain relievers are readily available and inexpensive,” said study author Kyle Arnold, MD, of the University of Washington in Seattle and a member of the American Academy of Neurology. “If these results can be confirmed by a controlled study, they could guide us to possible treatment options for people after a concussion.”

The cohort study was conducted by the NCAA and US Department of Defense CARE Consortium and looked at NCAA athletes and military cadets who had concussions. A total of 813 people took over-the-counter pain relievers such as acetaminophen or ibuprofen and other non-steroidal anti-inflammatory drugs after their concussion and 848 people did not take any pain relievers.

Researchers looked at the amount of time it took the athletes to be cleared to return to activities with no restrictions at both 50% recovery and 90% recovery, meaning when 50% of the athletes in the study recovered and then later when 90% recovered.

People who took the pain relievers were 20% more likely to have a faster time before they were cleared to return to activities with no restrictions than those who did not take pain relievers. Those who took the medications were cleared at 50% recovery an average of two days faster, and at 90% recovery an average of seven days faster than those who took no medication.

People who took pain relievers were also about 15% more likely to return to having no symptoms more quickly than those who did not take pain relievers. At 50% recovery, those taking the medications had no symptoms one day sooner than those not taking the medications. At 90% recovery, they had no symptoms three days sooner.

Those who took pain relievers also had lower scores on tests of how severe their symptoms were overall and how severe their headaches were.

The researchers also found that the earlier people took the pain relievers after the injury, the faster they recovered. For instance, at 50% recovery, those who started using pain relievers on the first day of their injury returned to play and had resolution of symptoms approximately eight days faster than those who started taking them after five or more days.

There was no difference between the type of pain reliever taken and how quickly people recovered.

“Early medication use appeared to be linked to shorter recovery times, but these findings require further validation through controlled trials,” Arnold said. “In the meantime, these preliminary results may help inform potential treatment options for people recovering from concussions, but additional studies are needed to provide more definitive recommendations.”

Powered by WPeMatico

Increased risk of acute kidney injury associated with chronic obstructive pulmonary disease: Study

A new study published in the journal of Renal Failure showed that patients with chronic obstructive pulmonary disease (COPD) have a high risk of acute kidney injury (AKI) and acute kidney disease (AKD).

About 50% of patients in intensive care units and 7%–18% of hospitalized patients suffer from acute kidney damage, which is linked to poorer clinical outcomes and increased mortality. The association between COPD, renal function, and mortality is highlighted by the prognosis of patients with AKI who have COPD. After acute kidney injury (AKI), persistent renal pathophysiological processes are referred to as acute kidney disease. The Kidney Disease: Clinical Practice Recommendations for Improving Global Outcomes (KDIGO) recommendations from 2012 state that AKI is characterized by a reduction in urine output (<0.5 mL/kg/h) within 7 days or a 1.5-fold rise in serum creatinine (Scr) from baseline.

The patients with chronic obstructive pulmonary disease and the mortality rate from COPD based on acute/subacute renal damage are poorly understood in relation to acute kidney injury (AKI) and acute kidney disease. Using online apps for clinical decision-making, this study creates machine learning models to predict AKI, AKD, and mortality in patients with COPD.

This study included 2,829 inpatients from January 2016 to December 2018. 20% of the data was used for testing, while the remaining 80% was used for training. Model performance was assessed using a variety of measures, and 8 machine learning techniques were employed. The decision-making process was shown using SHAP. Web apps for detecting high-risk patients were developed using the top models, as determined by AUROC.

AKI and AKD had incidence rates of 13.71% and 15.11%, respectively and 4.84% was the total mortality rate. With AUROC values of 0.815, 0.827, and 0.934 in AKI, AKD, and mortality, respectively, LightGBM demonstrated the greatest performance. Scr, neutrophil percentage, cystatin c, BUN, and LDH were important predictors of AKI. Age, AKI grade, HDL-C, Scr, and BUN were the main predictors of AKD.

The usage of dopamine and adrenaline medications, cystatin C, albumin, renal function trajectory, and neutrophil percentage were the main predictors of death. The prediction procedure for each patient was shown visually by force charts. Overall, patients with COPD have a notable incidence of AKI and AKD. Trajectories of acute and subacute renal damage are essential for forecasting death in individuals with COPD. 

Source:

Jin, M., Ma, L., Li, B., Huang, X., & Chen, M. (2025). Comparative analysis of left atrial volume and strain parameters in hemodialysis vs. peritoneal dialysis patients using four-dimensional automatic quantification technology. Renal Failure, 47(1), 2485390. https://doi.org/10.1080/0886022X.2025.2485390

Powered by WPeMatico

Single-dose psychedelic boosts brain flexibility for weeks, peer-reviewed study finds

In a groundbreaking research study, University of Michigan researchers have discovered that a single dose of a psychedelic compound can enhance cognitive flexibility-the brain’s ability to adapt to changing circumstances-or weeks after administration, potentially revolutionizing treatments for depression, PTSD, and neurodegenerative diseases.

The study, published today in the journal Psychedelics, demonstrates that mice treated with a single dose of 25CN-NBOH, a selective serotonin 2A receptor agonist, showed markedly improved performance in reversal learning tasks compared to control groups when tested 2-3 weeks after treatment.

Key Findings

“What makes this discovery particularly significant is the sustained duration of cognitive benefits following just one psychedelic dose,” explains Professor Omar J. Ahmed, the study’s senior, corresponding author from the University of Michigan’s Department of Psychology. “We observed enhanced learning adaptability that persisted for weeks, suggesting these compounds may induce lasting and behaviorally meaningful neuroplasticity changes in the prefrontal cortex.”

Using an innovative automated sequential learning paradigm, researchers measured how effectively mice could adapt to rule reversals-a standard test for cognitive flexibility. The psychedelic-treated mice demonstrated superior adaptability compared to saline controls, with enhanced task efficiency, higher percentages of correct trials, and increased reward acquisition during the reversal phase.

Implications for Brain Science

The results complement existing cellular research showing psychedelic-induced structural remodeling in the prefrontal cortex but uniquely demonstrate sustained cognitive benefits persisting long after the immediate effects of the drug have dissipated.

As interest in psychedelic medicine continues to grow, this research raises intriguing questions about how psychedelics might reshape neural pathways governing flexible thinking. Could these compounds potentially reopen critical periods of brain plasticity? What molecular mechanisms underlie these long-lasting cognitive improvements? How might the timing and frequency of administration affect long-term neuroplasticity?

“The current study focused on the long-term effects of a single psychedelic dose. A key question is what happens with two, three, or even twenty doses taken over several months. Is every additional dose increasingly beneficial for flexible learning or is there a plateau effect or even a negative effect of too many doses? These are important questions to answer next in the quest to make psychedelic medicine more rational and mechanistic,” according to Dr. Ahmed.

Sex Differences and Clinical Potential

Importantly, the study found that both male and female mice showed significant improvements in cognitive flexibility, suggesting the potential broad applicability of psychedelic therapy across biological sexes.

“The most striking aspect of our findings is that these cognitive benefits were measured 15-20 days after a single psychedelic administration,” notes Elizabeth J. Brouns, first author of the study. “This suggests that a single dose of a psychedelic isn’t just temporarily altering perception, but potentially inducing lasting beneficial changes in brain function.”

Methodological Advances

The study’s automated behavioral task represents a significant methodological advance for evaluating flexible learning, enabling researchers to efficiently evaluate cognitive flexibility in future investigations of psychedelic compounds. This high-throughput approach could accelerate the development of targeted psychedelic therapies for specific cognitive deficits.

Reference:

Elizabeth J. Brouns et al, Single-dose psychedelic enhances cognitive flexibility and reversal learning in mice weeks after administration, Psychedelics (2025). DOI: 10.61373/pp025r.0002.

Powered by WPeMatico

Minor Drug Law Violations Can Now Be Settled Without Trial: Health Ministry Issues Rules

New Delhi: The Ministry of Health and Family Welfare has notified the Drugs and Cosmetics (Compounding of Offences) Rules, 2025, allowing pharmaceutical companies and individuals to settle certain minor offences without facing full criminal trials under the Drugs and Cosmetics Act, 1940. The notification was officially published in the Gazette of India on April 24, 2025.

The move aims to decongest the court system, offer regulatory relief for minor violations, and streamline compliance under India’s evolving drug and cosmetic regulation framework.

The move follows the draft rules published last year, where public feedback was invited. The Central Government has introduced these rules under the powers conferred by Section 32B and Section 33 of the Drugs and Cosmetics Act, 1940, after considering public objections and suggestions to the draft rules published earlier in July 2024.

“Objections and suggestions received from the public on the said draft rules have been considered by the Central Government.”

Who Can Apply for Compounding?

The rules specify that any individual or company involved in the manufacturing, sale, import, or distribution of drugs, medical devices, or cosmetics can apply for compounding, either before or after prosecution begins.

“The applicant may, either before or after institution of prosecution, make an application to the compounding authority under section 32B of the Act in the Form along with such relevant informations and documents, to the compounding authority for compounding of the offence.”

Designation of Compounding Authorities

The Central and State Governments will appoint officers, not below the rank of licensing authorities, to act as compounding authorities for handling such cases.

“The Central Government may, for the purposes of these rules, by notification in the Official Gazette, appoint any officer not below the rank of reporting authority under these rules, as compounding authorityy for the purpose of exercising powers and functions of the Central Government under these rules and for taking measures with respect to matters arises from these rules.”

Similarly,

“The State Government may, for the purposes of these rules, by notification in the Official Gazette, appoint any officer not below the rank of licensing authority under the Act as compounding authority for the purpose of exercising such powers and functions of the State Government under these rules and for taking measures with respect to matters arisen from these rules.”

Procedure to Compound an Offence

Once an application is filed, the compounding authority will call for a report from the concerned licensing authority or reporting officer, review the matter, and then either allow or reject the application based on findings.

“The compounding authority after taking into account the contents of the said application may, by order, either allow the application indicating the compounding amount and grant him immunity from prosecution in terms of rule 6 or reject such application: Provided that the application shall not be rejected unless an opportunity has been given to the applicant of being heard and the grounds of such rejection are mentioned in such order.”

Payment of Compounding Amount

If the offence is compounded, the applicant is required to pay the compounding amount within 30 days of receiving the order.

“The applicant shall, within a period of thirty days from the date of receipt of order under sub-rule (3) allowing the compounding of offences, pay the compounding amount t, as ordered to be paid by the compounding authority and shall furnish the proof of such payment to the compounding authority: Provided that the compounding amount once paid shall not be refunded except in cases where the Court rejects grant of immunity from prosecution.”

Conditions and Withdrawal of Immunity

Immunity from prosecution may be withdrawn if the applicant:

Fails to pay the compounding amount, or

Is found to have concealed material information or given false evidence.

“An immunity granted to a person under rule 6 shall stand withdrawn,if such person fails to pay any sum specified in the order of compounding passed by the Compounding authority, under sub-rule(3) of rule 5 within the time specified in such order or fails to comply with any other conditions subject to which the immunity was granted and thereupon the provisions of the Act shall apply as if no such immunity had been granted.”

Further,

“An immunity granted to a person under sub-rule(1) above may, at anytime, be withdrawn by the Compounding authority, if satisfies that such person had, in the course of the compounding proceedings, concealed any particulars, material or had given false evidence, and thereupon such person may be tried for the offence with respect to which immunity has been granted or for any other offence that appears to have been committed by him in connection with the compounding proceedings and there upon the provisions of the Act, shall apply as if no such immunity had been granted.”

To view the official Gazette, click on the link below:

https://medicaldialogues.in/pdf_upload/262711-284799.pdf

Powered by WPeMatico

5 booked for defrauding a man of Rs 15 lakh in MBBS admission scam

In yet another medical admission fraud case, 5 individuals have been booked for duping around Rs 15 lakh from a man on the pretext of securing admission in MBBS in ESIC Medical College, Faridabad.

The victim has been identified as Sharma, a resident of Sector-55, Faridabad. He was duped of about Rs 15 lakh to get his daughter admitted to MBBS in ESIC Medical College. The accused has been identified as Manoj Sharma, his wife Monika, Shubham Tiwari, Priyanka and Krishna.

For more information, click on the link below:

Powered by WPeMatico